ES2195428T3 - Metodo para preparar oxidos de tetrahidrobenzotiepina enriquecidos enantiometricamente. - Google Patents

Metodo para preparar oxidos de tetrahidrobenzotiepina enriquecidos enantiometricamente.

Info

Publication number
ES2195428T3
ES2195428T3 ES98962044T ES98962044T ES2195428T3 ES 2195428 T3 ES2195428 T3 ES 2195428T3 ES 98962044 T ES98962044 T ES 98962044T ES 98962044 T ES98962044 T ES 98962044T ES 2195428 T3 ES2195428 T3 ES 2195428T3
Authority
ES
Spain
Prior art keywords
heterocyclyl
alkynyl
cycloalkyl
alkenyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98962044T
Other languages
English (en)
Inventor
James Li
Ching-Cheng Wang
David B Reitz
Victor Snieckus
Horng-Chih Huang
Andrew J Carpenter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of ES2195428T3 publication Critical patent/ES2195428T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Un método para preparar un tetrahidrobenzotiepin-1-óxido enriquecido enantioméricamente que tiene la **fórmula** en la que: R1 y R2 se seleccionan independientemente entre el grupo compuesto por H, alquilo, alquenilo, alquinilo, cicloalquilo, arilo y heteroarilo; R3 se selecciona entre el grupo compuesto por H, alquilo, alquenilo, alquinilo, arilo, cicloalquilo, heterociclilo, heterociclilo cuaternario, OR24, SR15, S(O)R15, SO2R15 y SO3R15, donde el alquilo, alquenilo, alquinilo, arilo, cicloalquilo, heterociclilo, heterociclilo cuaternario y heteroarilo cuaternario pueden estar substituidos con uno o más grupos substituyentes seleccionados independientemente entre el grupo compuesto por alquilo, alquenilo, alquinilo, polialquilo, poliéter, arilo, haloalquilo, cicloalquilo, heterociclilo, arilalquilo, heterociclilo cuaternario, heteroarilo cuaternario, halógeno, oxo, OR19, NR19R20, SR19, S(O)R19, SO2R19, SO3R19, NR19OR20, NR19NR20R21, NO2, CO2R19, CN, OM, SO2OM, SO2NR19R20, C(O)NR19R20, C(O)OM, COR19, P(O)R19R20, P+R19R20R21A-, P(OR19)OR20, S+R19R20A- y N+R15R17R18A-.
ES98962044T 1997-12-19 1998-12-16 Metodo para preparar oxidos de tetrahidrobenzotiepina enriquecidos enantiometricamente. Expired - Lifetime ES2195428T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6817097P 1997-12-19 1997-12-19

Publications (1)

Publication Number Publication Date
ES2195428T3 true ES2195428T3 (es) 2003-12-01

Family

ID=22080853

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98962044T Expired - Lifetime ES2195428T3 (es) 1997-12-19 1998-12-16 Metodo para preparar oxidos de tetrahidrobenzotiepina enriquecidos enantiometricamente.

Country Status (18)

Country Link
US (2) US6369220B1 (es)
EP (1) EP1042314B1 (es)
JP (1) JP2001526284A (es)
KR (1) KR20010015884A (es)
CN (2) CN1106395C (es)
AT (1) ATE234829T1 (es)
AU (1) AU1721399A (es)
BR (1) BR9814300A (es)
DE (1) DE69812419T2 (es)
DK (1) DK1042314T3 (es)
ES (1) ES2195428T3 (es)
HU (1) HUP0101193A3 (es)
IL (1) IL136864A (es)
PT (1) PT1042314E (es)
RU (1) RU2236406C2 (es)
UA (1) UA67764C2 (es)
WO (1) WO1999032478A1 (es)
ZA (1) ZA9811648B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DK1140184T3 (da) 1998-12-23 2003-09-29 Searle Llc Kombinationer af cholesterylestertransferproteinhæmmere og nikotinsyrederivater til hjertekar indikationer
EP1286984A2 (en) 2000-03-10 2003-03-05 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
PL216023B1 (pl) 2001-09-08 2014-02-28 Astrazeneca Ab Pochodna benzotiadiazepiny, kompozycja farmaceutyczna zawierajaca pochodna benzotiadiazepiny oraz zastosowania pochodnej benzotiadiazepiny
US6740663B2 (en) * 2001-11-02 2004-05-25 G.D. Searle, Llc Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
AU2003207431A1 (en) 2002-01-17 2003-09-02 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
KR20070026392A (ko) 2004-02-27 2007-03-08 아사히 가세이 파마 가부시키가이샤 신규 벤조티아제핀 및 벤조티에핀 화합물
EP2367554A4 (en) 2008-11-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid reflux inhibitor for the treatment of obesity and diabetes
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
ES2586931T3 (es) 2010-11-04 2016-10-19 Albireo Ab Inhibidores de IBAT para el tratamiento de enfermedades hepáticas
RU2619215C2 (ru) 2010-11-08 2017-05-12 Альбирео Аб Фармацевтическая комбинация, включающая ibat-ингибитор и связующее желчной кислоты
CN102558250B (zh) * 2010-12-14 2015-01-14 王芃 一种艾杜糖醛酸及其衍生物的制备方法
KR102051031B1 (ko) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
KR20160003664A (ko) 2013-03-15 2016-01-11 루메나 파마수티컬즈, 인코포레이티드 바렛 식도 및 위식도 역류 질환 치료용 담즙산 재순환 억제제
EP2968230A2 (en) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
US10012627B2 (en) 2013-03-15 2018-07-03 Georgetown University Determining stereoisomeric excess, concentration and absolute configuration
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
EP3413875B1 (en) 2016-02-09 2020-01-29 Albireo AB Cholestyramine pellets and methods for preparation thereof
EP3413878B1 (en) 2016-02-09 2021-04-14 Albireo AB Oral cholestyramine formulation and use thereof
EP3413877B1 (en) 2016-02-09 2021-04-07 Albireo AB Oral cholestyramine formulation and use thereof
CN110996915B (zh) 2017-08-09 2023-10-03 阿尔比里奥公司 考来烯胺丸粒、口服考来烯胺制剂及其用途
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
MX2020013839A (es) 2018-06-20 2021-03-25 Albireo Ab Formulacion farmaceutica de odevixibat.
WO2020028396A1 (en) 2018-07-30 2020-02-06 Georgetown University Chirality sensing with molecular click chemistry probes
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
WO2020056012A1 (en) 2018-09-11 2020-03-19 Georgetown University Quantitative auxiliary-free chirality sensing with a metal probe
CN109516971B (zh) * 2018-11-26 2020-09-25 山东永浩新材料科技有限公司 一种电池级硫酸乙烯酯的合成方法
TWI835997B (zh) 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
RS63899B1 (sr) 2019-02-06 2023-02-28 Albireo Ab Benzotiadiazepinska jedinjenja i njihova upotreba kao modulatora žučnih kiselina
CA3129826A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Methods for treating cholestasis
EP4069359B1 (en) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP7665620B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
BR112022010505A2 (pt) 2019-12-04 2022-09-06 Albireo Ab Compostos de benzotia(di)azepina e seu uso como moduladores do ácido biliar
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
AU2021390172A1 (en) 2020-12-04 2023-06-22 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
PY2373529A (es) * 2022-09-14 2024-03-25 Mirum Pharmaceuticals Inc Maralixibat formas sólidas, intermedios y procesos de hacer la misma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59144777A (ja) 1983-02-04 1984-08-18 Tokawa Tetsuo ベンゾチアゼピン誘導体の光学分割法
US5559017A (en) 1989-08-09 1996-09-24 E. R. Squibb & Sons, Inc. Microbial reduction of benzazepines and benzothiazepine derivatives
TW197435B (es) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
IT1249318B (it) 1991-05-23 1995-02-22 Zambon Spa Processo per la preparazione di benzotiazepine per ciclizzazione con acidi fosfonici
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
BR9508916A (pt) * 1994-09-13 1997-12-30 Monsanto Co "Novas benzotiepinas tendo atividade como inibidores de transporte do ácido biliar ileal e absorção de taurocolato"
NZ331813A (en) 1996-03-11 2001-03-30 G Benzothiepine compounds having activity as inhibitors of ileal bile acid transport and taurocholate uptake

Also Published As

Publication number Publication date
KR20010015884A (ko) 2001-02-26
HK1034971A1 (en) 2001-11-09
ZA9811648B (en) 1999-12-20
CN1439638A (zh) 2003-09-03
BR9814300A (pt) 2002-02-05
US6369220B1 (en) 2002-04-09
JP2001526284A (ja) 2001-12-18
EP1042314B1 (en) 2003-03-19
IL136864A0 (en) 2001-06-14
IL136864A (en) 2004-07-25
EP1042314A1 (en) 2000-10-11
US6875877B2 (en) 2005-04-05
PT1042314E (pt) 2003-07-31
HUP0101193A3 (en) 2001-12-28
RU2236406C2 (ru) 2004-09-20
ATE234829T1 (de) 2003-04-15
DK1042314T3 (da) 2003-07-14
DE69812419D1 (de) 2003-04-24
HUP0101193A2 (hu) 2001-08-28
AU1721399A (en) 1999-07-12
CN1284953A (zh) 2001-02-21
WO1999032478A1 (en) 1999-07-01
CN1106395C (zh) 2003-04-23
UA67764C2 (uk) 2004-07-15
US20020188119A1 (en) 2002-12-12
DE69812419T2 (de) 2003-08-14

Similar Documents

Publication Publication Date Title
ATE442853T1 (de) Selektive antibakterielle mittel
DE69534300D1 (de) Neues multimerisierendes reagenz
AR013693A1 (es) Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
ES2033049T3 (es) Procedimiento para preparar derivados de oxa- o tia-zolina.
ATE244404T1 (de) Zusammensetzungen und verfahren zur hemmung der licht-induzierten inaktivierung von biologischen reagenzien
ATE353973T1 (de) Die verwendung der 3'-wesentlichen bearbeitungswirksamkeit von dns-polymerase
ES2171040T3 (es) Derivados de esteres hidroxiaceticos y su utilizacion como intermediarios de sintesis.
FI944304A0 (fi) Akrylaattiryhmillä modifioidut organopolysiloksaanit
ATE137805T1 (de) Verfahren zur erhöhung von chemilumineszenz
ES2171964T3 (es) Esteres dibenzodihidropiridinecarboxilicos y su uso en metodos de ensayo quimiluminiscente.
CO4930274A1 (es) Tiazol bencenosulfonamidas como agonistas b3 para el trata- miento de la diabetes y la obesidad
BR9701843A (pt) Acilação enzimática
ES2099800T3 (es) Dihidropiridinas utilizables en la terapia antitumoral.
AR004965A1 (es) Procedimiento de preparacion de derivados de fenilimidazolidina
PT1072598E (pt) Derivados de pirazolinona
DE59009532D1 (de) Verwendung von 1-Arylsemicarbaziden zur Stabilisierung von Enzymsubstraten, entsprechende Verfahren und diagnositsches Mittel enthaltend einen solchen Stabilisator.
DE3787112D1 (de) Menschliche Pankreaselastase I.
DE69813534D1 (de) Verfahren zur herstellung von iodhaltigen kontrastmitteln und zwischenprodukten dafür
AR009105A1 (es) Derivados de n-(benzotiazol-2-il) piperidina-1-etanamina, su preparacion y aplicacion en terapeutica
ES2195803T1 (es) Monomeros y oligomeros de silicona que tienen un grupo funcional carboxilo.
ATE47592T1 (de) Piperidinderivate und diese enthaltende fungizide sowie verfahren zur bekaempfung von pilzen.
DE59914636D1 (de) Stabilisierung von biologischen Flüssigkeiten durch Zusatz von Sterinestern
MX9303753A (es) Dihidropiridinas anilladas y composiciones farmaceuticas que las contienen.
ES8706637A1 (es) Un procedimiento para preparar derivados de piridina
EP1118659A4 (en) EXPRESSION SYSTEMS FOR THE EXPRESSION OF FUNCTIONAL NUCLEIC ACIDS